Filters
Telomerase activity as a novel prognostic factor in multiple myeloma (NC7043)
Telomerase assay in multiple myeloma is new perspective prognostic factor in multiple myeloma The use od hTERT as tumor antigen is promising new treatment modality and could circumvent limitation of current vaccina...
EC - Imunologie
- 2002 - 2004 •
- 2 700 tis. Kč •
- 2 615 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2002 - 1. 1. 2004
Uznané náklady
Podpora ze státního rozpočtu (97%)
Poskytovatel: Ministerstvo zdravotnictví
Evaluation of Cellular Immunity and Molecular Analysis of Myeloma-Specific T cells in Patients with Multiple Myeloma (NC7475)
The aim of this study is to identify and characterize myeloma-specific T cells in patients with multiple myeloma. Immunocompetent cells will be evaluated before, during and after immunotherapy in patients with multiple<...
FD - Onkologie a hematologie
- 2003 - 2005 •
- 2 498 tis. Kč •
- 2 404 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2003 - 1. 1. 2005
Uznané náklady
Podpora ze státního rozpočtu (96%)
Poskytovatel: Ministerstvo zdravotnictví
The assessment of apoptosis and proliferative indices of plasma cells in patiens with multiple myeloma. (NC6212)
and immunohistological apoptosis examination) of myeloma plasmocytes in various phases of multiple myeloma course and their relationship to clinical and laboratory characteristics. Assesment of proliferative characteristic...
FD - Onkologie a hematologie
- 2000 - 2002 •
- 1 507 tis. Kč •
- 1 495 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2000 - 1. 1. 2002
Uznané náklady
Podpora ze státního rozpočtu (99%)
Poskytovatel: Ministerstvo zdravotnictví
Inhibitors of angiogenesis in multiple myeloma (NR8076)
Aim of the project is evaluation of the concentrations of angiogenesis inhibitors in patiens with multiple myeloma importance. Concentration of angiogenesis inhibitors in plasma and bone marrow plasma will be verified by ELISA. Angi...
FD - Onkologie a hematologie
- 2004 - 2006 •
- 1 640 tis. Kč •
- 1 629 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2004 - 1. 1. 2006
Uznané náklady
Podpora ze státního rozpočtu (99%)
Poskytovatel: Ministerstvo zdravotnictví
Use of monoclonal immunoglobulin for preparation of antitumor vaccine in patients with multiple myeloma (NC6763)
Isolation of Id protein from plasmapheresis product of patients with MM is possible in sufficient amount for repeated vaccination Imunomagnetic separetion is used to prepared myeloma cell suspension from bone marrow aspirate with more than 7...
FD - Onkologie a hematologie
- 2001 - 2003 •
- 1 893 tis. Kč •
- 1 864 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2001 - 1. 1. 2003
Uznané náklady
Podpora ze státního rozpočtu (98%)
Poskytovatel: Ministerstvo zdravotnictví
Immunotherapy Using Different Tumor Antigens in The Treatment of Multiple Myeloma (NR8945)
anti-tumor T-lymphocytes at patients with multiple myeloma. Clinical partThe aim of this project is to find an optimal strategy of T cell stimulation using dendritic cells loaded with different myeloma antigens. Irradiated...
FD - Onkologie a hematologie
- 2006 - 2009 •
- 6 929 tis. Kč •
- 6 587 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2006 - 31. 12. 2009
Uznané náklady
Podpora ze státního rozpočtu (95%)
Poskytovatel: Ministerstvo zdravotnictví
Prognostic significance of clonal chromosome aberration in new methods of multiple myeloma treatment (NR9317)
1. Clonal chromosome aberration in immunofluorescent labeling of malignant plasma cells using interphase fluorescence in situ hybridization has powerful prognostic significance in patient with multiple myeloma. 2. The prognostic sig...
FD - Onkologie a hematologie
- 2007 - 2009 •
- 3 798 tis. Kč •
- 3 787 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2007 - 31. 12. 2009
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Molecular-cytogenetic analysis of marked plasma cells and prognostic significance of clonal chromosomal aberrations in multiple myeloma (NR8183)
Detection of selected clonal chromosomal aberrations in immunofluorescence-marked plasma cells in patients with multiple myeloma using molecular cytogenetic methods. Evaluation of the impact of selected chromosomal abnormalities on ...
FD - Onkologie a hematologie
- 2004 - 2007 •
- 3 329 tis. Kč •
- 3 091 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2004 - 31. 12. 2007
Uznané náklady
Podpora ze státního rozpočtu (93%)
Poskytovatel: Ministerstvo zdravotnictví
Optimalization of the therapy of myeloma patients in Czech republic (NR9225)
Coordination of data collection and analysis of the patients with multiple myeloma in Czech republic - incidence, prognostic factors, results of therapy and survival. The aim is identification of risk-adapted and cost-effective ther...
FD - Onkologie a hematologie
- 2007 - 2009 •
- 5 945 tis. Kč •
- 5 642 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2007 - 31. 12. 2009
Uznané náklady
Podpora ze státního rozpočtu (95%)
Poskytovatel: Ministerstvo zdravotnictví
The detection of residual disease after high-dose therapy in multiple myeloma (NC4535)
The detection of residual disease after high-dose therapy in multiple myeloma by flow cytometry using specific antibodies against the palsma cells.......
FD - Onkologie a hematologie
- 1998 - 2000 •
- 814 tis. Kč •
- 768 tis. Kč •
- MZ
Řešení projektu: 1. 1. 1998 - 1. 1. 2000
Uznané náklady
Podpora ze státního rozpočtu (94%)
Poskytovatel: Ministerstvo zdravotnictví
- 1 - 10 out of 1 078